levopidon 40 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 40 mg
levopidon 45 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 45 mg
levopidon 50 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 50 mg
levopidon 55 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 55 mg
levopidon 5 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 5 mg
levopidon 60 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 60 mg
levopidon 65 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 65 mg
levopidon 70 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 70 mg
levopidon 75 mg oral opløsning, enkeltdosisbeholder
dne pharma as - levomethadonhydrochlorid - oral opløsning, enkeltdosisbeholder - 75 mg
verzenios
eli lilly nederland b.v. - abemaciclib - bryst neoplasmer - antineoplastiske midler - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.